Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Hwk-007
Endometrial Cancer, Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-Squamous Egfr Wt Nsclc, Proc
Phase I
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Feb 11, 2026
―
Adagrasib, Nab-Sirolimus
Nsclc, Advanced Cancer, Metastatic Cancer, Solid Tumor, Adult, Malignant Neoplastic Disease
Phase I
Terminated
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Apr 12, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Whitehawk Therapeutics (WHWK) have in its pipeline
WHWK is currently developing the following drugs: Hwk-007, Adagrasib, Nab-Sirolimus. These drug candidates are in various stages of clinical development as the company works toward FDA approval.